Painful sex, dryness, and lost desire are treatable.
We are a medical practice led by Dr. Zaher Merhi, devoted entirely to women's sexual longevity — keeping sexual function, tissue, and hormones healthy for the rest of your life. Not a spa. Not a telehealth prescription. A physician, in a room, treating the thing itself.
What you were told · What it actually was
"That's normal at your age."
Genitourinary syndrome of menopause
Affects an estimated 50–70% of menopausal women. Chronic and progressive — it does not resolve on its own.
"Try a lubricant."
Vulvovaginal atrophy
Lubricants relieve friction for an hour. They don't change the tissue underneath, which is what's actually thinning.
"Sex is different after menopause."
Dyspareunia
Persistent pain with intercourse. In women who have it, it is most often moderate to severe — and it is treatable.
"You're just tired. Or stressed."
Hypoactive sexual desire disorder
Roughly 16 million American women over 50 report low sexual desire. Testosterone and DHEA are measurable, and often part of the answer.
"Some women just get more UTIs."
Urogenital atrophy & microbiome disruption
Recurrent infection and urgency are part of the same estrogen-related syndrome as the dryness — and are assessed together, not separately.
Sexual longevity
/ˈsek.ʃu.əl lɒnˈdʒev.ə.ti/
The practice of keeping sexual function, genital tissue, and the hormones that govern them healthy across a full lifespan — treated as ongoing medical care rather than as something that simply ends.
Longevity medicine has spent a decade on hearts, muscle, and brains. It skipped this entirely. A woman today can expect to live thirty to forty years after menopause, and almost no one is treating the part of her body that changes first and gets asked about least.
What we treat -
Pain with intercourse
Burning, tearing, or aching during or after sex — including pain that started gradually enough that you adjusted around it before naming it.
Dyspareunia · Vestibulodynia · Vaginal stenosis
Desire that disappeared
Loss of interest, arousal, or responsiveness — particularly when it arrived suddenly, after surgery, or alongside other menopausal changes.
HSDD · Androgen insufficiency · Arousal disorder
Sensation & orgasm
Reduced sensitivity, difficulty reaching orgasm, or orgasm that has become muted. Often driven by blood flow and tissue health, both of which are treatable.
Anorgasmia · Reduced genital blood flow
Dryness & tissue change
Persistent dryness, thinning, loss of elasticity, irritation, or light bleeding. The underlying tissue change is measurable, and it is what we treat.
Vulvovaginal atrophy · GSM · Lichen sclerosus screening
Urinary symptoms
Urgency, frequency, leaking, burning, and UTIs that keep returning. Part of the same syndrome as the dryness — which is why treating one often helps the other.
Recurrent UTI · Urgency · Stress incontinence
After surgery/cancer therapy
Changes following hysterectomy, removal of the ovaries, chemotherapy, or years on an aromatase inhibitor — when hormones may not be an option.
Surgical menopause · Treatment-induced atrophy
Which treatment, for which problem
Condition
Primary treatment
Supporting
You were told there was nothing left to try.
Women with a history of hormone-receptor-positive breast cancer are routinely advised against systemic hormone therapy — then offered little beyond a moisturizer, despite having higher rates of genitourinary symptoms than women who never had cancer.
Every in-clinic therapy in our protocol works locally, without systemic hormones: platelet-rich plasma prepared from your own blood, medical ozone, and red and near-infrared light. We coordinate with your oncologist as a matter of routine, and we don't prescribe against their guidance.
50–70%
of menopausal women are affected by genitourinary syndrome of menopause — and the rate runs higher still among breast cancer survivors
Twenty-five years on the tissue everyone else stopped studying.
Dr. Zaher Merhi is a board-certified endocrinologist who has spent his career on female hormonal aging — and, unusually, on the regenerative procedures that act on tissue itself rather than only on the prescription.
He was the first physician in the United States to develop platelet-rich plasma protocols in this field, has published more than 110 peer-reviewed papers, and has been named among the top 2% of scientists worldwide. He holds academic appointments at Albert Einstein College of Medicine and Maimonides Medical Center, and conducts every consultation here personally.
110+
peer-reviewed publications
25
years in practice
Top 2%
of scientists worldwide
2×
featured in Forbes